公开(公告)号：JP2011097946A

公开(公告)日：2011-05-19

申请号：JP2010280298

申请日：2010-12-16

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： GHAYUR TARIQ ,  LABKOVSKY BORIS ,  VOSS JEFFREY W ,  GREEN LARRY ,  BABCOOK JOHN ,  JIA XIAO-CHI ,  WIELER JAMES ,  KANG JASPAL SINGH ,  HEDBERG BRAD

IPC: C12N15/09 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/573 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/40 ,  A61K47/42 ,  A61P1/04 ,  A61P1/16 ,  A61P3/00 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/04 ,  A61P17/06 ,  A61P17/14 ,  A61P19/00 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P27/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/16 ,  A61P31/18 ,  A61P31/20 ,  A61P33/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/06 ,  A61P37/08 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/532 ,  G01N33/68

CPC classification number: G01N33/6869 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: PROBLEM TO BE SOLVED: To provide an antibody which binds to human interleukin-18 (hIL-18), to provide a method for producing the same; and to provide a method for using the same. SOLUTION: There are provided a neutrally binding protein which is an antibody comprising immune globulin heavy chain and light chain having specific amino acid sequences and specifically binding to human IL-18, and has an ability to neutralize IL-18; a method for producing the antibody; and a use for detecting hIL-18 or treating a human testee suffering from a disease wherein the activity of hIL-18 is harmful. COPYRIGHT: (C)2011,JPO&INPIT

Abstract translation: 待解决的问题：提供与人白细胞介素-18（hIL-18）结合的抗体，以提供其生产方法; 并提供使用该方法。 提供了中和结合蛋白，其是包含具有特异性氨基酸序列并且特异性结合人IL-18的免疫球蛋白重链和轻链的抗体，并且具有中和IL-18的能力; 抗体制备方法; 以及用于检测hIL-18或治疗患有其中hIL-18的活性是有害的疾病的人类受试者的用途。 版权所有（C）2011，JPO＆INPIT

公开(公告)号：JP2012139223A

公开(公告)日：2012-07-26

申请号：JP2012028435

申请日：2012-02-13

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： GHAYUR TARIQ ,  LABKOVSKY BORIS ,  VOSS JEFFREY W ,  GREEN LARRY ,  BABCOOK JOHN ,  JIA XIAO-CHI ,  WIELER JAMES ,  KANG JASPAL SINGH ,  HEDBERG BRAD

IPC: C12N15/09 ,  A61K39/395 ,  A61K45/00 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/40 ,  A61K47/42 ,  A61P1/16 ,  A61P3/08 ,  A61P5/14 ,  A61P5/16 ,  A61P5/50 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/08 ,  A61P13/12 ,  A61P15/00 ,  A61P15/08 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/14 ,  A61P31/20 ,  A61P33/00 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K14/715 ,  C07K16/24 ,  C12N1/11 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/68

CPC classification number: G01N33/6869 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: PROBLEM TO BE SOLVED: To provide a new family of a binding protein, and a human antibody and its fragment, which have a capacity to bind to IL-18, binds with a high affinity, and neutralizes the IL-18 by binding to it.SOLUTION: The present invention includes an IL-18 binding protein, particularly an antibody which binds to a human interleukin-18 (hIL-18). Concretely, the invention relates to an antibody which is an entirely human antibody. The antibody has the high affinity for the hIL-18, and/or neutralizes an hIL-18 activity in vitro and in vivo. The antibody can be of a full-length or an antigen binding portion thereof. The method of making the antibody is also provided. The antibody, or the antibody portion is useful for detecting the hIL-18, and for medically treating a human subject suffering from a disorder in which the hIL-18 is detrimental, based on an hIL-18 activity inhibition.

Abstract translation: 要解决的问题：提供具有结合IL-18的能力的结合蛋白的新家族和人抗体及其片段以高亲和力结合，并通过以下方式中和IL-18： 绑定到它 解决方案：本发明包括IL-18结合蛋白，特别是结合人白细胞介素-18（hIL-18）的抗体。 具体地，本发明涉及一种完全人抗体的抗体。 该抗体对hIL-18具有高亲和力，和/或在体外和体内中和hIL-18活性。 抗体可以是全长或其抗原结合部分。 还提供了制备抗体的方法。 基于hIL-18活性抑制，抗体或抗体部分可用于检测hIL-18，以及用于医学治疗患有其中hIL-18是有害的病症的人类受试者。 版权所有（C）2012，JPO＆INPIT

公开(公告)号：JP2009149665A

公开(公告)日：2009-07-09

申请号：JP2009029449

申请日：2009-02-12

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： DEVRIES PETER J ,  GREEN LARRY L ,  OSTROW DAVID H ,  REILLY EDWARD B ,  WIELER JAMES

IPC: C07K16/28 ,  A61K39/395 ,  A61P7/06

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/92

Abstract: PROBLEM TO BE SOLVED: To provide an antibody binding to and activating an erythropoietin receptor and an antibody fragment thereof. SOLUTION: The antibody binding to and activating the erythropoietin receptor, an antibody fragment selected from a group consisting of an Fab fragment, an Fab' fragment, an F(ab')2 fragment and an Fv fragment thereof, a method for modulating the endogeneous activity of the erythropoietin receptor in a mammal using the antibody, and a pharmaceutical composition containing the antibody are provided. COPYRIGHT: (C)2009,JPO&INPIT

Abstract translation: 待解决的问题：提供结合并激活促红细胞生成素受体的抗体及其抗体片段。 解决方案：结合并激活促红细胞生成素受体的抗体，选自Fab片段，Fab'片段，F（ab'）2片段及其Fv片段的抗体片段， 使用抗体调节哺乳动物中促红细胞生成素受体的内源性活性，并提供含有该抗体的药物组合物。 版权所有（C）2009，JPO＆INPIT

公开(公告)号：JP2011097947A

公开(公告)日：2011-05-19

申请号：JP2010280299

申请日：2010-12-16

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： GHAYUR TARIQ ,  LABKOVSKY BORIS ,  VOSS JEFFREY W ,  GREEN LARRY ,  BABCOOK JOHN ,  JIA XIAO-CHI ,  WIELER JAMES ,  KANG JASPAL SINGH ,  HEDBERG BRAD

IPC: C12N15/09 ,  A61K31/4375 ,  A61K31/519 ,  A61K31/56 ,  A61K31/70 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/40 ,  A61K47/42 ,  A61P1/04 ,  A61P1/16 ,  A61P3/00 ,  A61P3/02 ,  A61P3/10 ,  A61P5/00 ,  A61P7/06 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/14 ,  A61P31/18 ,  A61P31/20 ,  A61P33/00 ,  A61P35/00 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/02 ,  C12P21/08 ,  C12Q1/02 ,  G01N33/68

CPC classification number: G01N33/6869 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: PROBLEM TO BE SOLVED: To provide an IL-18 binding protein, especially an antibody binding to human interleukin-18 (hIL-18). SOLUTION: There is provided an antibody which is a perfect human antibody. A preferable antibody has high affinity with hIL-18, or neutralizes the activity of hIL-18 in vitro or in vivo. The antibody may be a total length antibody or an antigen-binding portion thereof. A method for producing the antibody and a method for using the same are also provided. The antibody or antibody portion is useful for detecting hIL-18 and for inhibiting the activity of hIL-18, for example, in a human testee suffering from a disease wherein the activity of the hIL-18 is harmful. COPYRIGHT: (C)2011,JPO&INPIT

Abstract translation: 要解决的问题：提供IL-18结合蛋白，特别是结合人白细胞介素-18（hIL-18）的抗体。 提供了一种完美的人抗体的抗体。 优选的抗体与hIL-18具有高亲和力，或在体外或体内中和hIL-18的活性。 抗体可以是全长抗体或其抗原结合部分。 还提供了生产抗体的方法及其使用方法。 抗体或抗体部分可用于检测hIL-18和用于抑制hIL-18的活性，例如在患有hIL-18的活性有害的疾病的人类受试者中。 版权所有（C）2011，JPO＆INPIT

公开(公告)号：WO2004035603A3

公开(公告)日：2006-04-27

申请号：PCT/US0332243

申请日：2003-10-14

Applicant: ABBOTT LAB

Inventor： DEVRIES PETER J ,  GREEN LARRY L ,  OSTROW DAVID H ,  REILLY EDWARD B ,  WIELER JAMES

IPC: C07K16/28 ,  C07K16/00 ,  A61K39/395 ,  A61K39/40 ,  C07H21/04 ,  C07K1/00

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/92

Abstract: The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.

Abstract translation: 本发明涉及结合并激活促红细胞生成素受体的抗体及其抗体片段。 本发明还涉及使用所述抗体以及含有所述抗体的药物组合物调节哺乳动物中促红细胞生成素受体的内源性活性的方法。

公开(公告)号：WO2005047307A3

公开(公告)日：2006-08-31

申请号：PCT/US2004037971

申请日：2004-11-12

Applicant: ABBOTT LAB ,  GHAYUR TARIQ ,  LABKOVSKY BORIS ,  VOSS JEFFREY W ,  GREEN LARRY ,  BABCOOK JOHN ,  JIA XIAO-CHI ,  WIELER JAMES ,  KANG JASPAL SINGH ,  HEDBERG BRAD

Inventor： GHAYUR TARIQ ,  LABKOVSKY BORIS ,  VOSS JEFFREY W ,  GREEN LARRY ,  BABCOOK JOHN ,  JIA XIAO-CHI ,  WIELER JAMES ,  KANG JASPAL SINGH ,  HEDBERG BRAD

IPC: C07K16/00 ,  A61K39/395 ,  C07H21/04 ,  C07K16/24 ,  C12N15/00 ,  G01N33/53 ,  G01N33/68

CPC classification number: G01N33/6869 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

Abstract translation: 本发明包括IL-18结合蛋白，特别是结合人白细胞介素-18（hIL-18）的抗体。 具体地，本发明涉及完全是人抗体的抗体。 优选的抗体对hIL-18具有高亲和力和/或在体外和体内中和hIL-18活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性，例如在患有hIL-18活性有害的病症的人类受试者中。

公开(公告)号：EP1685152A4

公开(公告)日：2008-04-16

申请号：EP04817825

申请日：2004-11-12

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  LABKOVSKY BORIS ,  VOSS JEFFREY W ,  GREEN LARRY ,  BABCOOK JOHN ,  JIA XIAO-CHI ,  WIELER JAMES ,  KANG JASPAL SINGH ,  HEDBERG BRAD

IPC: C07K16/00 ,  A61K39/395 ,  A61P19/02 ,  A61P37/06 ,  C07H21/04 ,  C07K16/24 ,  C12N15/00 ,  G01N33/53 ,  G01N33/68

CPC classification number: G01N33/6869 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：EP1578779A4

公开(公告)日：2011-11-16

申请号：EP03774776

申请日：2003-10-14

Applicant: ABBOTT LAB

Inventor： DEVRIES PETER J ,  GREEN LARRY L ,  OSTROW DAVID H ,  REILLY EDWARD B ,  WIELER JAMES

IPC: C07K16/00 ,  A61K39/395 ,  A61K39/40 ,  C07H21/04 ,  C07K1/00 ,  C07K16/28

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/92

公开(公告)号：AU2011224023B2

公开(公告)日：2012-09-13

申请号：AU2011224023

申请日：2011-09-13

Applicant: ABBOTT LAB

Inventor： LABKOVSKY BORIS ,  HEDBERG BRAD ,  WIELER JAMES ,  KANG JASPAL SINGH ,  JIA XIAO-CHI ,  BADCOOK JOHN ,  GREEN LARRY ,  GHAYUR TARIQ ,  VOSS JEFFERY W

IPC: C07K16/24 ,  G01N33/68

Abstract: IL -18 BINDING PRO TEINS Abstract The present invention encompasses IL-1 8 binding proteins, particularly antibodies that bind human interleukin- 18 (hIL- 18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hlL-18 and/or that neutralize hIL-1 8 activity in vitro and in vivo. An antibody of the io invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hlL- 18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hlL 18 activity is detrimental.

公开(公告)号：CA2543920A1

公开(公告)日：2005-05-26

申请号：CA2543920

申请日：2004-11-12

Applicant: ABBOTT LAB

Inventor： VOSS JEFFREY W ,  LABKOVSKY BORIS ,  GHAYUR TARIQ ,  KANG JASPAL SINGH ,  GREEN LARRY ,  HEDBERG BRAD ,  BABCOOK JOHN ,  JIA XIAO-CHI ,  WIELER JAMES

IPC: C12N15/13 ,  A61K39/395 ,  A61P37/00 ,  C07K16/24 ,  C12N1/11 ,  C12N1/15 ,  C12N1/21 ,  C12N5/10 ,  C12N15/63 ,  C12N15/70 ,  C12N15/79 ,  G01N33/68

Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.